Comparative efficacy of two angiotensin ii receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension

American Journal of Hypertension

Volumn 11, Issue 4 I, 1998, Pages 445-453

  Kassler Taub, Kenneth ^a   Littlejohn, Thomas ^b   Elliott, William ^c   Ruddy, Terrence ^d   Adler, Evelyn ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Piedmont Medical Research Associates   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Angiotensin II receptor antagonist; Irbesartan; Losartan; Mild to moderate hypertension; Pharmakokinetics; Placebo controlled study

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 0031800774     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00491-3     Document Type: Article

References (41)

1. Timmermans PBMWM, Wong CM, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
2. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 265:1993;826-834.
3. Vachharajani N, Chang S-Y, Shyu WC, et al. Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man (abst). Pharm Res. 12:1995;S418.
4. Necciari J, Denolle T, Le Coz F, et al. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abst). J Hypertens. 12:1994;88.
5. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects (Abst). Clin Pharmacol Ther. 61:1997;207.
6. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent . J Pharmacol Exp Ther. 252:1990;719-725.
7. Christophe B, Libon R, Cazaubon C, et al. Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat potential mechanisms of action . Eur J Pharmacol. 281:1995;161-171.
8. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent . J Pharmacol Exp Ther. 255:1990;211-217.
9. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 51:1992;513-521.
10. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 58:1995;641-649.
11. Johnston CI. Angiotensin receptor antagonists focus on losartan . Lancet. 346:1995;1403-1407.
12. US FDA Medical Review for Cozaar® (losartan potassium tablets), Rockville MD, April 5, 1995.
13. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists a new class of antihypertensive drugs . Arch Intern Med. 155:1995;1361-1368.
14. Ribstein J, Picard A, Armagnac C, et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects (abst). J Hypertens. 15:(suppl 4):1997;S117.
15. Pouleur HG. Clinical overview of irbesartan a new angiotensin II receptor antagonist . Am J Hypertens. 10:1997;318S-324S.
16. US FDA Medical Review for Avapro (irbesartan), Rockville, MD, September 30, 1997.
17. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 25:1995;1345-1350.
18. Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 11:1998;462-470.
19. Guthrie RM, Saini R, Hannah S, et al. Dose-related reductions in blood pressure with irbesartan, the angiotensin II receptor antagonist (abst). Am J Hypertens. 10:(4 part 2):1997;172A.
20. Kochar M, Guthrie R, Triscari J, et al. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension (abst). Am J Hypertens. 10:(4 part 2):1997;106A.
21. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan a preliminary report . Am J Hypertens. 5:1992;247S-251S.
22. 1 receptor antagonist irbesartan in hypertension. Hypertension. 25:1995;22-29.
23. Fogari R, Ambrosoli S, Corradi L, et al. 24-Hour blood pressure control by once daily irbesartan as assessed by ambulatory blood pressure monitoring. J Hypertens. 15:1997;1511-1518.
24. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
25. Christen Y, Waeber B, Nussberger J, et al. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens. 4:1991;350S-353S.
26. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers inhibition of pressor response to exogenous angiotensin I and II . Circulation. 83:1991;1333-1342.
27. Yun C-H, Lee HS, Lee H, et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes role of cytochrome P4503A(4) in formation of the active metabolite EXP3174 . Drug Metab Dispos. 23:1995;285-289.
28. Bork RW, Muto T, Beaune PH, et al. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem. 264:1989;910-919.
29. Guengerich FP. Oxidation of 17 α-ethinylestradiol by human liver cytochrome P-450. Mol Pharmacol. 33:1988;500-508.
30. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 155:1995;405-411.
31. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 153:1993;154-183.
32. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 157:1997;2413-2446.
33. Perloff D, Arim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation. 88:1993;2460-2470.
34. Recommendations for routine blood pressure measurement by indirect cuff sphygmamanometry. Am J Hypertens. 5:1992;207-209.
35. Zanchetti A, Chalmers JP, Arakawa K, et al. The 1993 guideline for the management of mild hypertension memorandum from WHO/ISH meeting . Hypertension. 22:1993;392-403.
36. Committee for Proprietary Medicinal Products, European Agency for the Evaluation of Medicinal Products: Note for guidance on clinical investigation on medicinal products in the treatment of hypertension. CPMP/EWP/238/95.
37. United States Food and Drug Administration, Division of Cardio-Renal Drug Products: Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Draft, May 9, 1988.
38. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2. Lancet. 225:1990;827-838.
39. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 49:1996;1787-1790.
40. Brunner HR, Delacrétaz E, Nussberger J, et al. Angiotensin II antagonists DuP 753 and TCV 116. J Hypertens. 12:1994;S29-S34.
41. Burnier M, Pechère-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade the confounding factor of acute water loading on the action of vasoactive systems . Am J Kidney Dis. 26:1995;108-115.